Previous close | 25.26 |
Open | 25.33 |
Bid | 25.41 x 4000 |
Ask | 25.46 x 2900 |
Day's range | 25.20 - 25.54 |
52-week range | 25.20 - 40.37 |
Volume | |
Avg. volume | 42,282,466 |
Market cap | 143.829B |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | 68.65 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.68 (6.65%) |
Ex-dividend date | 09 May 2024 |
1y target est | N/A |
Stock market investors brace for a big week of earnings and econ as Apple, Amazon, Big Pharma and The Fed all line up to deliver news.
Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.